List view / Grid view
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
Scientists identify thousands of novel enhancers linked to neuronal differentiation and neuropsychiatric disorders, offering new pathways for drug discovery and potential therapeutic targets.
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Huntsman Cancer Institute researchers have identified a gene variant in Andean populations that could predict blood cancer treatment outcomes and potentially lead to targeted therapies.
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
